35 related articles for article (PubMed ID: 14634383)
1. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Nomogram Predicting the Prognosis of Renal Cell Carcinoma After Nephrectomy.
Xia M; Yang H; Wang Y; Yin K; Bian X; Chen J; Shuang W
Cancer Manag Res; 2020; 12():4461-4473. PubMed ID: 32606940
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.
Sharma T; Tajzler C; Kapoor A
Curr Oncol; 2018 Oct; 25(5):e444-e453. PubMed ID: 30464696
[TBL] [Abstract][Full Text] [Related]
4. The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer.
Nayan M; Hamilton RJ; Finelli A; Austin PC; Kulkarni GS; Juurlink DN
Can Urol Assoc J; 2017 Jun; 11(6):167-171. PubMed ID: 28652873
[TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic factors for renal parenchymal, pelvis, and ureter cancers in SEER registries: collaborative stage data collection system, version 2.
Altekruse SF; Dickie L; Wu XC; Hsieh MC; Wu M; Lee R; Delacroix S
Cancer; 2014 Dec; 120 Suppl 23(0 23):3826-35. PubMed ID: 25412394
[TBL] [Abstract][Full Text] [Related]
6. Renal cell carcinoma.
Jonasch E; Gao J; Rathmell WK
BMJ; 2014 Nov; 349():g4797. PubMed ID: 25385470
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment.
Kyoda Y; Kobayashi K; Hirobe M; Shindo T; Fukuta F; Hashimoto K; Tanaka T; Tonooka A; Kitamura H; Takahashi S; Masumori N; Hasegawa T; Tsukamoto T
Int J Clin Oncol; 2014 Feb; 19(1):146-51. PubMed ID: 23404486
[TBL] [Abstract][Full Text] [Related]
8. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis.
Wu X; Weng L; Li X; Guo C; Pal SK; Jin JM; Li Y; Nelson RA; Mu B; Onami SH; Wu JJ; Ruel NH; Wilczynski SP; Gao H; Covarrubias M; Figlin RA; Weiss LM; Wu H
PLoS One; 2012; 7(5):e35661. PubMed ID: 22623952
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma deep sequencing: recent developments.
Farber LJ; Furge K; Teh BT
Curr Oncol Rep; 2012 Jun; 14(3):240-8. PubMed ID: 22535504
[TBL] [Abstract][Full Text] [Related]
10. Staging of renal cell carcinoma: Current concepts.
Lam JS; Klatte T; Breda A
Indian J Urol; 2009; 25(4):446-54. PubMed ID: 19955666
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.
Kapoor A; Gharajeh A; Sheikh A; Pinthus J
Curr Oncol; 2009 May; 16 Suppl 1(Suppl 1):S60-6. PubMed ID: 19478895
[TBL] [Abstract][Full Text] [Related]
12. Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.
Downs TM; Schultzel M; Shi H; Sanders C; Tahir Z; Sadler GR
Crit Rev Oncol Hematol; 2009 Apr; 70(1):59-70. PubMed ID: 18993080
[TBL] [Abstract][Full Text] [Related]
13. Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma.
Berger DA; Megwalu II; Vlahiotis A; Radwan MH; Serrano MF; Humphrey PA; Piccirillo JF; Kibel AS
Urology; 2008 Aug; 72(2):359-63. PubMed ID: 18468663
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification and prognostication of renal cell carcinoma.
Ficarra V; Galfano A; Novara G; Iafrate M; Brunelli M; Secco S; Cavalleri S; Martignoni G; Artibani W
World J Urol; 2008 Apr; 26(2):115-25. PubMed ID: 18392834
[TBL] [Abstract][Full Text] [Related]
15. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value.
Kempkensteffen C; Hinz S; Christoph F; Krause H; Magheli A; Schrader M; Schostak M; Miller K; Weikert S
J Cancer Res Clin Oncol; 2008 May; 134(5):543-50. PubMed ID: 17922292
[TBL] [Abstract][Full Text] [Related]
16. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy.
Klatte T; Pantuck AJ; Kleid MD; Belldegrun AS
Rev Urol; 2007; 9(2):47-56. PubMed ID: 17592537
[TBL] [Abstract][Full Text] [Related]
17. Surveillance following radical or partial nephrectomy for renal cell carcinoma.
Lam JS; Leppert JT; Figlin RA; Belldegrun AS
Curr Urol Rep; 2005 Feb; 6(1):7-18. PubMed ID: 15610692
[TBL] [Abstract][Full Text] [Related]
18. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population.
Han KR; Bleumer I; Pantuck AJ; Kim HL; Dorey FJ; Janzen NK; Zisman A; Dinney CP; Wood CG; Swanson DA; Said JW; Figlin RA; Mulders PF; Belldegrun AS
J Urol; 2003 Dec; 170(6 Pt 1):2221-4. PubMed ID: 14634383
[TBL] [Abstract][Full Text] [Related]
19. Use of the University of California Los Angeles Integrated Staging System (UISS) to predict survival in localized renal cell carcinoma in an Asian population.
Ng CF; Wan SH; Wong A; Lai FM; Hui P; Cheng CW
Int Urol Nephrol; 2007; 39(3):699-703. PubMed ID: 17180738
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
